[ Leukemia & Lymphoma Society – Translational Research Program | Research Funding ]
Event details
Date | 29.10.2021 |
Category | Call for proposal |
Aim: The Leukemia & Lymphoma Society, Inc. (LLS) is a national voluntary health agency dedicated to the conquest of hematologic malignancies and relevant premalignant conditions.
The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness. Applications are sought that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative. The application should have a clear plan for the eventual clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.
Funding: max. $600,000
Duration: 3 years
Eligibility: LLS welcomes applications from both US citizens and non-citizens, as well as applicants who are performing research outside the US. Applicants must be appointed to a not-for-profit institution at the time of application submission. Applicants must hold a PhD, MD, DVM, or equivalent degree. The TRP program is intended for independent, established researchers. Therefore, applicants holding positions such as post-doctoral fellows, instructors, etc. are discouraged from applying.
How to Apply: The two-stage application process begins with submission of a Letter of Intent (LOI). All submissions must use the LLS Research Portal at https://lls.fluxx.io. Templates for all application forms are downloadable on the Portal. If the LOI is approved, the Applicant will be notified by an automated email stating that he/she may proceed to the Full Application phase. Signatures of the Applicant and Sponsor Institution Officials are not required for submission of the LOI, but are required for the full proposal.
Deadline: Letter of Intent – 29 October 2021 (3PM ET)
Full Application – 21 January 2022 (3PM ET)
Further information For any other questions, please contact the Research Office
The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness. Applications are sought that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative. The application should have a clear plan for the eventual clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.
Funding: max. $600,000
Duration: 3 years
Eligibility: LLS welcomes applications from both US citizens and non-citizens, as well as applicants who are performing research outside the US. Applicants must be appointed to a not-for-profit institution at the time of application submission. Applicants must hold a PhD, MD, DVM, or equivalent degree. The TRP program is intended for independent, established researchers. Therefore, applicants holding positions such as post-doctoral fellows, instructors, etc. are discouraged from applying.
How to Apply: The two-stage application process begins with submission of a Letter of Intent (LOI). All submissions must use the LLS Research Portal at https://lls.fluxx.io. Templates for all application forms are downloadable on the Portal. If the LOI is approved, the Applicant will be notified by an automated email stating that he/she may proceed to the Full Application phase. Signatures of the Applicant and Sponsor Institution Officials are not required for submission of the LOI, but are required for the full proposal.
Deadline: Letter of Intent – 29 October 2021 (3PM ET)
Full Application – 21 January 2022 (3PM ET)
Further information For any other questions, please contact the Research Office
Practical information
- General public
- Free